A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Trial Profile

A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Pancrelipase (Primary)
  • Indications Cystic fibrosis; Exocrine pancreatic insufficiency
  • Focus Therapeutic Use
  • Sponsors Abbott Healthcare Products
  • Most Recent Events

    • 13 Mar 2018 New trial record
    • 20 Jul 2009 Results published in the Trial Registry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top